Relevant bibliographies by topics / Biological dose

Academic literature on the topic 'Biological dose'

Author: Grafiati
Published: 23 September 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Biological dose.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Biological dose"

1

Oftedal, Per. "Biological low-dose radiation effects." Mutation Research/Reviews in Genetic Toxicology 258, no. 2 (September 1991): 191–205. http://dx.doi.org/10.1016/0165-1110(91)90009-k.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Alber, Markus. "Normal tissue dose-effect models in biological dose optimisation." Zeitschrift für Medizinische Physik 18, no. 2 (June 2008): 102–10. http://dx.doi.org/10.1016/j.zemedi.2007.08.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jaikuna, Tanwiwat, Phatchareewan Khadsiri, Nisa Chawapun, Suwit Saekho, and Ekkasit Tharavichitkul. "Isobio software: biological dose distribution and biological dose volume histogram from physical dose conversion using linear-quadratic-linear model." Journal of Contemporary Brachytherapy 1 (2017): 44–51. http://dx.doi.org/10.5114/jcb.2017.66082.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

IWASAKI, Toshiyasu, and Masanori TOMITA. "Biological Effects of Low dose/Low dose-rate Ionizing Radiation." Journal of the Atomic Energy Society of Japan 51, no. 9 (2009): 668–73. http://dx.doi.org/10.3327/jaesjb.51.9_668.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pinto, M., and A. Amaral. "Biological dose assessment after low-dose overexposures in nuclear medicine." Radiation Protection Dosimetry 162, no. 3 (November 13, 2013): 254–59. http://dx.doi.org/10.1093/rpd/nct285.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Koteles, G. J. "Biological responses in low-dose range." International Journal of Low Radiation 2, no. 1/2 (2006): 97. http://dx.doi.org/10.1504/ijlr.2006.007900.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Joiner, M. C., S. A. Krueger, G. D. Wilson, and B. Marples. "41 Low-dose hypersensitivity: Biological mechanism." Radiotherapy and Oncology 78 (March 2006): S15. http://dx.doi.org/10.1016/s0167-8140(06)80535-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nenot, J. C. "Biological Indicators for Radiation Dose Assessment." International Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine 52, no. 1 (January 1987): 177. http://dx.doi.org/10.1080/09553008714551601.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Chen, Y., X. K. Yan, J. Du, Z. D. Wang, X. Q. Zhang, F. G. Zeng, and P. K. Zhou. "Biological dose estimation for accidental supra-high dose gamma-ray exposure." Radiation Measurements 46, no. 9 (September 2011): 837–41. http://dx.doi.org/10.1016/j.radmeas.2011.04.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zhang, Qinghui, Suqing Tian, and Giovanni Borasi. "A new definition of biological effective dose: The dose distribution effects." Physica Medica 31, no. 8 (December 2015): 1060–64. http://dx.doi.org/10.1016/j.ejmp.2015.07.145.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Biological dose"

1

Fenwick, John David. "Biological modelling of pelvic radiotherapy : potential gains from conformal techniques." Thesis, Institute of Cancer Research (University Of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.322314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Verma, Malvika. "Gastric resident systems for large dose drug delivery." Thesis, Massachusetts Institute of Technology, 2019. https://hdl.handle.net/1721.1/123066.

Full text
Abstract:
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Biological Engineering, 2019
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 154-176).
Lack of medication adherence is a worldwide problem. As many as 50-70% of patients have trouble following treatment recommendations. Whereas adherence is driven by many factors including the socioeconomic status of a patient and the quality of the health care team, drug regimen complexity also affects treatment outcomes. For example, adherence decreases as the number of pills per dose and the number of doses per day increases. For diseases where potent medications are available, depot formulations provide sustained drug release to simplify dosing. For diseases lacking potent compounds for treatment, there remains an unmet need for depot systems that could transform medication adherence. Tuberculosis (TB) is one such disease with a high pill burden, where poor patient adherence to the treatment regimen is a major cause of treatment failure and contributes to the emergence of drug-resistant TB strains.
For example, an average 60-kg patient with TB needs to take 3.3 g of antibiotics per day, which is a dose that exceeds the largest swallowable capsule and current depot systems. According to the World Health Organization (WHO), 10 million people developed TB in 2017 with a global economic burden amounting to $12 billion annually. This thesis presents a solution to the challenge of prolonged dosing for regimens such as TB that require multigram drug dosing. First, a gastric resident system (GRS) compatible with transesophageal administration was designed using biocompatible materials. The GRS consists of a series of drug pills on a coiled superelastic nitinol wire; the ends are protected with a retainer and tubing. Safe administration, gastric retention for 1 month, and retrieval of the GRS were demonstrated in a swine model. Next, sustained release formulations for 6 TB antibiotics were formulated into drug-polymer pills, and first-order drug release kinetics were achieved in vitro.
Then, the GRS was demonstrated to be capable of safely encapsulating and releasing 10 grams of an antibiotic over the period of weeks in a swine model. Lastly, end-user assessment was evaluated with a field questionnaire in India and an economic model to estimate the impact of the GRS on the health care system. There are multiple applications of the GRS in the field of infectious diseases, as well as for other indications where multigram depots could impart meaningful benefits to patients, helping maximize adherence to their medication.
"Funding and Resources: -- Bill and Melinda Gates Foundation -- National Institutes of Health -- National Science Foundation Graduate Research Fellowship -- MIT Tata Center and leadership team for believing in and guiding our project"
by Malvika Verma.
Ph. D.
Ph.D. Massachusetts Institute of Technology, Department of Biological Engineering
APA, Harvard, Vancouver, ISO, and other styles
3

Hollmark, Malin. "Absorbed dose and biological effect in light ion therapy." Doctoral thesis, Stockholm : Medical Radiation Physics, Stockholm university together with KI, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-7756.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zackrisson, Björn. "Biological effects of high energy radiation and ultra high dose rates." Doctoral thesis, Umeå universitet, Onkologisk radiobiologi, 1991. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-96889.

Full text
Abstract:
Recently a powerful electron accelerator, 50 MeV race-track microtron, has been taken into clinical use. This gives the opportunity to treat patients with higher x-ray and electron energies than before. Furthermore, treatments can be performed were the entire fractional dose can be delivered in parts of a second. The relative biological effectiveness (RBE) of high energy photons (up to 50 MV) was studied in vitro and in vivo. Oxygen enhancement ratio (OER) of 50 MV photons and RBE of 50 MeV electrons were investigated in vitro. Single-fraction experiments, in vitro, using V-79 Chinese hamster fibroblasts showed an RBE for 50 MV x-rays of approximately 1.1 at surviving fraction 0.01, with reference to the response to 4 MV x- rays. No significant difference in OER could be demonstrated. Fractionation experiments were carried out to establish the RBE at the clinically relevant dose level, 2 Gy. The RBE calculated for the 2 Gy/fraction experiments was 1.17. The RBEs for 20 MV x-rays and 50 MeV electrons were equal to one. In order to investigate the validity of these results, the jejunal crypt microcolony assay in mice was used to determine the RBE of 50 MV x-rays. The RBE for 50 MV x-rays in this case was estimated to be 1.06 at crypt surviving fraction 0.1. Photonuclear processes are proposed as one possible explanation to the higher RBE for 50 MV x-rays. Several studies of biological response to ionizing radiation of high absorbed dose rates have been performed, often with conflicting results. With the aim of investigating whether a difference in effect between irradiation at high dose rates and at conventional dose rates could be verified, pulsed 50 MeV electrons from a clinical accelerator were used for experiments with ultra high dose rates (mean dose rate: 3.8 x 10^ Gy/s) in comparison to conventional (mean dose rate: 9.6 x 10"^ Gy/s). V-79 cells were irradiated in vitro under both oxic and anoxic conditions. No significant difference in relative biological effectiveness (RBE) or oxygen enhancement ratio (OER) was observed for ultra high dose rates compared to conventional dose rates. A central issue in clinical radiobiological research is the prediction of responses to different radiation qualities. The choice of cell survival and dose response model greatly influences the results. In this context the relationship between theory and model is emphasized. Generally, the interpretations of experimental data are dependent on the model. Cell survival models are systematized with respect to their relations to radiobiological theories of cell kill. The growing knowledge of biological, physical, and chemical mechanisms is reflected in the formulation of new models. This study shows that recent modelling has been more oriented towards the stochastic fluctuations connected to radiation energy deposition. This implies that the traditional cell survival models ought to be complemented by models of stochastic energy deposition processes at the intracellular level.

S. 1-44: sammanfattning, s. 47-130: 5 uppsatser


digitalisering@umu
APA, Harvard, Vancouver, ISO, and other styles
5

Hann, Robert Mark. "Estimation of the median effective dose in quantal response biological assay." Thesis, Liverpool John Moores University, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.299065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ali, Yasmine. "Biological dose estimation in hadrontherapy using the GATE Monte Carlo simulation platform." Thesis, Lyon, 2021. http://www.theses.fr/2021LYSE1329.

Full text
Abstract:
Un des challenges en hadronthérapie est l'estimation de la dose biologique. Les systèmes de planification de traitement (TPS) doivent optimiser les faisceaux de traitement en prenant en compte la prédiction de la dose biologique en plus de la prédiction de la dose physique. Pour estimer la dose biologique, des modèles biophysiques ont été développés tels que les modèles mMKM et NanOx. Les paramètres d'entrée de ces modèles peuvent être estimés grâce à des codes de calculs Monte Carlo en structure de trace. Nous utilisons les codes Geant4-DNA et LPCHEM et les comparons pour évaluer leurs différences. Les deux codes peuvent simuler les radiations ionisantes jusqu'à l'eV ainsi que la production d'espèces radiolytiques suite à la radiolyse de l'eau entre la picoseconde et la microseconde. Les modèles biophysiques permettent des calculs de dose complexes à l'échelle du voxel en les couplant à des codes de calcul Monte Carlo. Nous avons développé un outil pour la plateforme de calcul Monte Carlo GATE, le "Biodose actor", dans le but d'estimer la dose biologique pour des pics de Bragg étalés issus de lignes cliniques et précliniques, irradiant avec des faisceaux de protons, d'ions hélium et d'ions carbone. Nous avons comparé les codes Geant4-DNA et LPCHEM pout la simulation de spectres nanodosimétriques dans le cœur de trace d’ion et la production d'espèce radiolytiques dans l’eau par des particules chargées (10 MeV protons). Les spectres totaux d’énergie spécifique dans des cibles nanométriques ainsi que les rendements d’espèces radiolytiques pour les deux codes sont en bon accord. En plus de l’implémentation du BioDose actor dans GATE, l’outil a été testé et validé avec des données expérimentales de survie cellulaire obtenues grâce à différents pics de Bragg étalés. Cet outil facilitera les comparaisons et évaluation des diffèrents modèles biophysiques
One of the current challenges in hadrontherapy is the evaluation of the biological effects due to microscopic pattern of energy deposition of ions. Treatment Planning Systems (TPS) should optimize beam parameters taking into account their predictions through the calculation of the biological dose in addition to the physical dose. To estimate the biological dose, biophysics models have been developed such as the mMKM and NanOx models. Some input parameters of the models are generally estimated with Monte Carlo Track Structure Codes such as Geant4-DNA and LPCHEM codes. Both codes are able to perform the simulation of ion and electron transport in water down to some eV as well as the evaluation of the chemical species generated during water radiolysis between 10-12 and 10-6 s. In this work, we first compared the outcome of LPCHEM and Geant4-DNA in terms of specific energy in nano and micro targets as well as yields of chemical species (input of the biophysical models). Then, we enhanced the GATE Monte Carlo simulation platform by creating a “Biodose actor” in order to estimate the biological dose for different clinical Spread-out Bragg Peaks (SOBP) with hydrogen, helium and carbon ion beams. We performed the first comparison between the LPCHEM and Geant4-DNA codes for the simulation of nanodosimetry spectra in the track core and the production of chemical species yields for water irradiations with charged particles (10 MeV protons). The total specific energy spectra in nanometric targets and the chemical yields predicted by the two codes are in good agreement. Besides the implementation of the BioDose actor in GATE has been tested and validated with comparison against experimental cell survival obtained in several SOBP. This tool paves the way of facilitated benchmarking between different models and evaluation approaches
APA, Harvard, Vancouver, ISO, and other styles
7

Gayzik, Francis Scott. "Optimal Control of Thermal Damage to Biological Materials." Thesis, Virginia Tech, 2003. http://hdl.handle.net/10919/35087.

Full text
Abstract:
Hyperthermia is a cancer treatment modality that raises cancerous tissue to cytotoxic temperature levels for roughly 30 to 45 minutes. Hyperthermia treatment planning refers to the use of computational models to optimize the heating protocol to be used in a hyperthermia treatment. This thesis presents a method to optimize a hyperthermia treatment heating protocol. An algorithm is developed which recovers a heating protocol that will cause a desired amount of thermal damage within a region of tissue. The optimization algorithm is validated experimentally on an albumen tissue phantom.

The transient temperature distribution within the region is simulated using a two- dimensional, finite-difference model of the Pennes bioheat equation. The relationship between temperature and time is integrated to produce a damage field according to two different models; Henriques'' model and the thermal dose model (Moritz and Henriques (1947)), (Sapareto and Dewey (1984)). A minimization algorithm is developed which re duces the value of an objective function based on the squared difference between an optimal and calculated damage field. Either damage model can be used in the minimization algorithm. The adjoint problem in conjunction with the conjugate gradient method is used to minimize the objective function of the control problem.

The flexibility of the minimization algorithm is proven experimentally and through a variety of simulations. With regards to the validation experiment, the optimal and recovered regions of permanent thermal damage are in good agreement for each test performed. A sensitivity analysis of the finite difference and damage models shows that the experimentally-obtained extent of damage is consistently within a tolerable error range.

Excellent agreement between the optimal and recovered damage fields is also found in simulations of hyperthermia treatments on perfused tissue. A simplified and complex model of the human skin were created for use within the algorithm. Minimizations using both the Henriques'' model and the thermal dose model in the objective function are performed. The Henriques'' damage model was found to be more desirable for use in the minimization algorithm than the thermal dose model because it is less computationally intensive and includes a mechanism to predict the threshold of permanent thermal damage. The performance of the minimization algorithm was not hindered by adding complexity to the skin model. The method presented here for optimizing hyperthermia treatments is shown to be robust and merits further investigation using more complicated patient models.
Master of Science

APA, Harvard, Vancouver, ISO, and other styles
8

Gayzik, F. Scott. "Optimal Control of Thermal Damage to Biological Materials." Thesis, Virginia Tech, 2004. http://hdl.handle.net/10919/35087.

Full text
Abstract:
Hyperthermia is a cancer treatment modality that raises cancerous tissue to cytotoxic temperature levels for roughly 30 to 45 minutes. Hyperthermia treatment planning refers to the use of computational models to optimize the heating protocol to be used in a hyperthermia treatment. This thesis presents a method to optimize a hyperthermia treatment heating protocol. An algorithm is developed which recovers a heating protocol that will cause a desired amount of thermal damage within a region of tissue. The optimization algorithm is validated experimentally on an albumen tissue phantom. The transient temperature distribution within the region is simulated using a two-dimensional, finite-difference model of the Pennes bioheat equation. The relationship between temperature and time is integrated to produce a damage field according to two different models; Henriques'' model and the thermal dose model (Moritz and Henriques (1947)), (Sapareto and Dewey (1984)). A minimization algorithm is developed which re duces the value of an objective function based on the squared difference between an optimal and calculated damage field. Either damage model can be used in the minimization algorithm. The adjoint problem in conjunction with the conjugate gradient method is used to minimize the objective function of the control problem. The flexibility of the minimization algorithm is proven experimentally and through a variety of simulations. With regards to the validation experiment, the optimal and recovered regions of permanent thermal damage are in good agreement for each test performed. A sensitivity analysis of the finite difference and damage models shows that the experimentally-obtained extent of damage is consistently within a tolerable error range. Excellent agreement between the optimal and recovered damage fields is also found in simulations of hyperthermia treatments on perfused tissue. A simplified and complex model of the human skin were created for use within the algorithm. Minimizations using both the Henriques'' model and the thermal dose model in the objective function are performed. The Henriques'' damage model was found to be more desirable for use in the minimization algorithm than the thermal dose model because it is less computationally intensive and includes a mechanism to predict the threshold of permanent thermal damage. The performance of the minimization algorithm was not hindered by adding complexity to the skin model. The method presented here for optimizing hyperthermia treatments is shown to be robust and merits further investigation using more complicated patient models.
Master of Science
APA, Harvard, Vancouver, ISO, and other styles
9

Harvey, Jane Ellen. "Long-term and high dose opioid medicine use in the U.K." Thesis, University of Nottingham, 2018. http://eprints.nottingham.ac.uk/52175/.

Full text
Abstract:
Introduction The number of prescriptions dispensed for opioid medicines has increased in the U.K. in the last two decades and studies have shown patients are receiving opioids for longer periods than in the past. There is a lack of evidence as to the effectiveness of these drugs when used long-term, as efficacy evidence is taken from short clinical trials in populations who do not have the comorbidities commonly seen in chronic pain patients. Large observational studies of patients prescribed opioid medicines outside of clinical trials, have identified that some patients taking long-term opioids are reporting they are still in high levels of pain. There is also a concern that patients are receiving high dosages of opioid medicines without effective pain relief. However, no studies in the U.K. have looked at the proportion of patients who continue to receive opioids (for all conditions) in the long-term or at high dosages so we do not know how opioid use develops in the U.K. Research from other countries has also identified that long-term and high dose use is linked to patient characteristics such as patient demographics and psychological and physical comorbidities. For example, a prior history of depression has been found to increase the risk of long-term and high dose use. This is of concern as this may indicate that patients may be potentially medicating the depression with the opioid. This may not be the case in the U.K. due to key factors such as the structure of the health system, so the aim of this thesis was to see if this phenomenon could potentially be occurring in the U.K. Methods This thesis was a retrospective observational cohort study of patients receiving opioid medicines for non-cancer conditions using data from a U.K. derived primary care database, the clinical practice research datalink (CPRD). Patients were included in the study if they received a prescription for opioid medication at any point in the year 2009 and followed, where possible to January 2015 (though data was collected for baseline variables prior to 2009). This thesis consists of a series of longitudinal analyses that attempt to define and describe the probability of long-term use and proportion of patients who receive high dosages in the U.K and seeks to understand how baseline characteristics (such as having a comorbid condition occurring before opioid use starts) affect the probability of long-term and high dose use. Competing risks methods were used to calculate the probability of continuation of opioid medicines (using death as a competing risk) and to determine long-term use. Cox regression models were used to determine whether baseline factors (such as prior antidepressant use) were associated with discontinuation of long-term use. Calculation of odds ratios were used to predict whether baseline characteristics predicted high dose use. Cox regression was also used to predict time to discontinuation of high dose use. Results In the U.K., 10.58% of patients received opioid medicines to treat non-cancer pain in the year 2009. Of the non-cancer patients included in the study, 41.41% were patients who received opioids in the six months prior to 2009 and the remaining were new users of opioid medicines. In the new user opioid group, 5.75% continued to be prescribed opioids for at least one year. When including new and existing users of opioid medicines, one in thirty people in the U.K. population who started opioids for non-cancer pain in 2009 were continuously prescribed opioids for a full year. Patients who were female, received an antidepressant before opioid use started and were in the youngest age category were more likely to continue opioid use past 2 years. The probability of continuing to take opioid medicines is higher in patients who have been receiving opioids for longer and are on higher dosages; in patients who had received over 10mg OMEQ for over two years, over half of patients continued to receive prescriptions for opioid medicines for the five year period study after 2009. In the U.K. population, one in a hundred opioid medicine users were prescribed a high dose (estimated dosage received >120mg oral morphine equivalents per day for at least 91 days) for non-cancer pain in their first 91 days of use in the year 2009. Patients receiving high dosages were likely to be receiving multiple opioid drug types and to receive preparations with multiple release profiles. In new users of opioid medication, the odds of high dose use were increased in patients who were younger (aged 18-49 years), had 3 or more comorbidities or were in receipt of an antidepressant or benzodiazepine and/or anti-anxiety drug before or after opioid use started. In new and existing users of opioid medicines, patients who were receiving high dosages were more likely to be diagnosed or be recorded with symptoms of depression or anxiety and to have been prescribed an antidepressant or benzodiazepine and/or other anti-anxiety drug in the youngest age group compared to the older age groups. Of the patients that were prescribed high dosages of opioid medicines for at least 91 days, 37.64% of patients did not have a second consecutive high dose quarter due to death or stopping high dose use. Almost one in five patients who had a high dose quarter continued to have a high dose for the next three years (22.98%). Older patients, patients prescribed weak opioids and/or tramadol discontinued high dose use at a faster rate than younger patients. Conclusion Both high dose and long-term use were found to be associated with a prior prescribing of antidepressants before opioid use started, suggesting that in the U.K. psychological comorbidities are associated with continued and high dose opioid use. Further work is required to measure outcomes within these groups and to understand the care that these patients have already received. Most patients who start opioid medicines in the U.K. stop taking them in their first year of use. However, of those who continue use past two years, a large proportion continue for the full five year period. Similarly, only a small proportion of patients receive high dosages of opioid medicines but once this use is established, many patients have a high probability of continuation. Further work should be undertaken to facilitate effective review of these patients in practice.
APA, Harvard, Vancouver, ISO, and other styles
10

Niebuhr, Nina Isabelle [Verfasser], and Joao [Akademischer Betreuer] Seco. "Biological Dose Accumulation in Image-guided Radiotherapy / Nina Isabelle Niebuhr ; Betreuer: Joao Seco." Heidelberg : Universitätsbibliothek Heidelberg, 2021. http://d-nb.info/1224684508/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Biological dose"

1

Loevinger, Robert. MIRD primer for absorbed dose calculations. New York, NY: Society of Nuclear Medicine, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hughes, Donald. Notes on ionizing radiation: Biological effects, quantities dose limits and regulations. Leeds: H and H Scientific Consultants, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tsutomu, Sugahara, Sagan Leonard A, and Aoyama Takashi, eds. Low dose irradiation and biological defense mechanisms: Proceedings of the International Conference on Low Dose Irradiation and Biological Defense Mechanisms, Kyoto, Japan, 12-16 July 1992. Amsterdam: Excerta Medica, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Takeshi, Yamada, ed. Biological effects of low dose radiation: Proceedings of the International Meeting on Biological Effects of Low Dose Radiation held in Cork, Ireland on 25-26 July 1999. Amsterdam: Elsevier, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Fujioka, Jeffrey T. Log-likelihood ratio tests for comparing dose-response data to the logistic function. Auke Bay, Alaska: National Oceanic and Atmospheric Administration, National Marine Fisheries Service, Northwest and Alaska Fisheries Center, Auke Bay Laboratory, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fujioka, Jeffrey T. Log-likelihood ratio tests for comparing dose-response data to the logistic function. Auke Bay, Alaska: National Oceanic and Atmospheric Administration, National Marine Fisheries Service, Northwest and Alaska Fisheries Center, Auke Bay Laboratory, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

L, Gledhill Barton, and Mauro Francesco, eds. New horizons in biological dosimetry: Proceedings of the International Symposium on Trends in Biological Dosimetry, held in Lerici, Italy, October 23-27, 1990. New York: Wiley-Liss, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

International Conference on Biological Effects of Large Dose Ionizing and Non-ionizing Radiation (1988 Hongzhou, China). Radiation biological effects modifiers and treatment: Proceedings of the International Conference on Biological Effects of Large Dose Ionizing and Non-ionizing Radiation, Hangzhou, March 29-April 1, 1988. Beijing, China: Society of Radiation Medicine and Protection, Chinese Medical Association, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Measurements, National Council on Radiation Protection and. The relative biological effectiveness of radiations of different quality: Recommendations of the National Council on Radiation Protection and Measurements. Bethesda, MD: The Council, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hanford Life Sciences Symposium (26th 1987 Richland, Wash.). Modeling for scaling to man: Biology, dosimetry, and response, [proceedings of the] 26th Hanford Life Sciences Symposium. Edited by Mahaffey Judith A. New York: Pergamon Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Biological dose"

1

Gruler, Hans. "Chemokinesis, Chemotaxis and Galvanotaxis Dose-Response Curves and Signal Chains." In Biological Motion, 396–414. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-51664-1_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nigg, H. N., and J. H. Stamper. "Biological Monitoring for Pesticide Dose Determination." In Biological Monitoring for Pesticide Exposure, 6–27. Washington, DC: American Chemical Society, 1988. http://dx.doi.org/10.1021/bk-1988-0382.ch001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Saunders, M. I. "Fractionation as a Biological Dose Modifier." In Progress and Perspective in the Treatment of Lung Cancer, 151–59. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59824-1_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bethge, Klaus, Gerhard Kraft, Peter Kreisler, and Gertrud Walter. "Radiation Safety and Dose Limitations." In Biological and Medical Physics, Biomedical Engineering, 89–99. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-662-08608-7_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mouttet-Audouard, Raphaëlle, Thomas Lacornerie, and Eric Lartigau. "Cyberknife, Dose Fractioning for Clinical Protocols." In Biological and Medical Physics, Biomedical Engineering, 51–65. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-31563-8_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ahn, Chul, Seung-Ho Kang, and Yang Xie. "Optimal Biological Dose for Molecularly Targeted Therapies." In Methods and Applications of Statistics in Clinical Trials, 496–505. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118596333.ch29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gamberoni, Giacomo, Evelina Lamma, Paola Mello, Piercamillo Pavesi, Sergio Storari, and Giuseppe Trocino. "Learning the Dose Adjustment for the Oral Anticoagulation Treatment." In Biological and Medical Data Analysis, 171–81. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-540-30547-7_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sherman, Arthur, Patricia Carroll, Rosa M. Santos, and Illani Atwater. "Glucose Dose Response of Pancreatic β-Cells: Experimental and Theoretical Results." In Transduction in Biological Systems, 123–41. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-5736-0_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Goldman, Marvin. "Retrospective Radiation Dose Assessment: An Overview of Physical and Biological Measures of Dose." In Ciba Foundation Symposium 203 - Health Impacts of Large Releases of Radionuclides, 178–87. Chichester, UK: John Wiley & Sons, Ltd., 2007. http://dx.doi.org/10.1002/9780470515006.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Barquinero, Joan Francesc, and Pere Puig. "Biological Dosimetry, Statistical Challenges: Biological Dosimetry After High-Dose Exposures to Ionizing Radiation." In Trends in Mathematics, 67–70. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55639-0_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Biological dose"

1

Hoopes, P. Jack, Alicia A. Petryk, Andrew J. Giustini, Robert V. Stigliano, Robert N. D'Angelo, Jennifer A. Tate, Shiraz M. Cassim, et al. "Nanoparticle-based cancer treatment: can delivered dose and biological dose be reliably modeled and quantified?" In SPIE BiOS, edited by Thomas P. Ryan. SPIE, 2011. http://dx.doi.org/10.1117/12.877026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Muflic, Lucian, and Ileana Ion. "ANTI-TUMOR NECROSIS FACTOR ALPHA BIOLOGIC THERAPY DOSE ADJUSTMENT NECESSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A CASE PRESENTATION." In NORDSCI International Conference Proceedings. Saima Consult Ltd, 2019. http://dx.doi.org/10.32008/nordsci2019/b1/v2/36.

Full text
Abstract:
Rheumatoid arthritis is an inflammatory disease characterized by chronic joint erosive processes, affecting approximately 1% of the population. [1] The pathogenic mechanisms processes involve the activation of pro-inflammatory cytokines, including TNF alpha. [2] The purpose of this case presentation is to elucidate a possible correlation between the high level of blood TNF alpha and the apparent lack of response to biologic therapy directed against this molecule. A female patient, aged 55 years, diagnosed with rheumatoid arthritis in 2006, presents an increased inflammatory biological syndrome. The patient was being treated biologically (adalimumab, and two years of etanercept previously. One year ago, the patient presents the elevation values of the blood tests commonly used to monitor the status of patients with inflammatory rheumatoid arthritis up to 2.5-3 x than normal values. Initially, this increase is considered to be due to a respiratory seasonal condition. We continued monitoring the status, after subsequent remission of these respiratory disorders, and we observed the persistence of those elevated test, this time without an obvious possible causing comorbidity. We decided to evaluate the current patient status and we obtained the following information: Biological syndrome currently moderately exceeds the maximum normal values. ESR was 47 mm/h and CRP 1.5 than the normal value. TNF alpha value determined by immunochemical methods with detection by chemiluminescence (CLIA) is 67.2 pg / mL Biological confirmation by determining serum TNF alpha and increased observation that the current level may be one explanation for the possible reactivation of the disease prompted us to continue the study in patients receiving anti-TNF alpha biologic. This study is ongoing. We can imagine this correlation between the level of TNF alpha and the degree of disease activity at least in the case of a group of patients treated with biological drugs. If this could be demonstrated, then perhaps we can expect a change in the curative approach of these patients, meaning that dose adjustment can be considered depending on the level of TNF alpha, and why not, depending on other cytokines that may be included in future studies.
APA, Harvard, Vancouver, ISO, and other styles
3

Doria, D., K. F. Kakolee, S. Kar, S. K. Litt, F. Fiorini, H. Ahmed, S. Green, et al. "Biological cell irradiation at ultrahigh dose rate employing laser driven protons." In LIGHT AT EXTREME INTENSITIES 2011. AIP, 2012. http://dx.doi.org/10.1063/1.4736777.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nose, Hiroyuki, Naruhiro Matsufuji, Yuki Kase, and Tatsuaki Kanai. "Biological dose distribution analysis with microdosimetry; experiment and monte carlo simulation." In 2007 IEEE Nuclear Science Symposium Conference Record. IEEE, 2007. http://dx.doi.org/10.1109/nssmic.2007.4437151.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shaowei, Wang. "Radiation Dose Evaluation of Marine Organisms for Coastal Nuclear Power Plant." In 2017 25th International Conference on Nuclear Engineering. American Society of Mechanical Engineers, 2017. http://dx.doi.org/10.1115/icone25-67832.

Full text
Abstract:
Fukushima nuclear accident has aroused concern about ionizing radiation damage to the marine environment. It is subjective to assess the accident’s effects on the marine ecological environment during different scholars, because of different understanding of nuclide release quantity, dose estimation models and parameters. To solve this problem, a gradually progressive research approach is designed based on a coastal nuclear power plant in study, which is “from influencing factors analyzing to biological dose assessment, and to uncertainty analysis”. First, the factors affecting the biological dose assessment will be analyzed, and then the concerns of the various factors and their impact on the results of the assessment will be discussed. Second, the biological dose will be assessed based on appropriate dose mode after selecting representative species and analyzing critical exposure pathway. Finally, the uncertainty of radionuclide release quantity, dilution factor, concentration factor, dose conversion factor will be analyzed. The study will provide reliable scientific bases to identify the factors impact biological dose assessment effectively, and improve the accuracy of the dose evaluation.
APA, Harvard, Vancouver, ISO, and other styles
6

Bolodon, Vladimir, and Eugene A. Chernitsky. "About nonlinearity of dependence of dose-effect in photodamage of biological membranes." In Laser Applications in Life Sciences: 5th International Conference, edited by Pavel A. Apanasevich, Nikolai I. Koroteev, Sergei G. Kruglik, and Victor N. Zadkov. SPIE, 1995. http://dx.doi.org/10.1117/12.197491.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Li, C. F., D. D. Li, and Z. C. Wang. "Apoptotic modulation role of caspase-9 and -3 in testicular cells induced by low dose radiation." In International Conference on Environmental Science and Biological Engineering. Southampton, UK: WIT Press, 2014. http://dx.doi.org/10.2495/esbe140421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wang, Xinyi, Jianlong Yang, Aili Zhang, and Lisa X. Xu. "Thermal Dose Images Enhance the Prediction of Local Tumor Progression After Multimode Ablation." In BIBE2021: The Fifth International Conference on Biological Information and Biomedical Engineering. New York, NY, USA: ACM, 2021. http://dx.doi.org/10.1145/3469678.3469694.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Assessment of Thyroid Absorbed Dose During Breast Radiotherapy with TLD and Treatment Planning Methods and Its Relation with Radiotherapy Field." In International Institute of Chemical, Biological & Environmental Engineering. International Institute of Chemical, Biological & Environmental Engineering, 2015. http://dx.doi.org/10.15242/iicbe.c0615096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Larionov, Pjotr M., Alexey N. Malov, Nikolai A. Maslov, and Anatoliy M. Orishich. "The effect of UV radiation dose on biological tissues' laser-induced fluorescence spectra." In SPIE Proceedings, edited by Valery V. Tuchin. SPIE, 2004. http://dx.doi.org/10.1117/12.579163.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Biological dose"

1

Bechtold, W. E., and R. B. Hayes. Biological monitoring to determine worker dose in a butadiene processing plant. Office of Scientific and Technical Information (OSTI), December 1995. http://dx.doi.org/10.2172/381369.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Eidson, A. Biological characterization of radiation exposure and dose estimates for inhaled uranium milling effluents. Office of Scientific and Technical Information (OSTI), June 1990. http://dx.doi.org/10.2172/6820217.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Auerbach, Scott, Chad Blystone, B. Alex Merrick, Georgia Roberts, Daniel Morgan, John Bucher, Michael DeVito, et al. NTP Research Report on In Vivo Repeat Dose Biological Potency Study of Triphenyl Phosphate (CAS No. 115-86-6) in Male Sprague Dawley Rats (Hsd: Sprague Dawley SD) (Gavage Studies). NIEHS, October 2018. http://dx.doi.org/10.22427/ntp-rr-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kleven, Henrik, Camille Landais, and Jakob Egholt Søgaard. Does Biology Drive Child Penalties? Evidence from Biological and Adoptive Families. Cambridge, MA: National Bureau of Economic Research, May 2020. http://dx.doi.org/10.3386/w27130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Wester, Ronald C. Bioavailability of Organic Solvents in soils: Input into Biologically Based Dose-Response Models for Human Risk Assessments. Office of Scientific and Technical Information (OSTI), June 1999. http://dx.doi.org/10.2172/828375.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wester, Ronald C. Bioavailability Of Organic Solvents In Soils: Input Into Biologically Based Dose-Response Models for Human Risk Assessments. Office of Scientific and Technical Information (OSTI), December 2000. http://dx.doi.org/10.2172/828376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wester, Ronald C. Bioavailability of Organic Solvents in Soils: Input into Biologically-Based Dose- Response Models for Human Risk Assessments. Office of Scientific and Technical Information (OSTI), June 2000. http://dx.doi.org/10.2172/828368.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Royette Tavernier, Ph.D., Royette Tavernier, Ph D. Battle of the clocks: Does your biological clock determine whether the timing of exercise impairs or promotes sleep? Experiment, October 2016. http://dx.doi.org/10.18258/8234.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Webster, R. C. Bioavailability of Organic Solvents in Soils: Input into Biologically Based Dose-Response Models for Human Risk Assessments - Final Report. Office of Scientific and Technical Information (OSTI), October 2000. http://dx.doi.org/10.2172/775523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wester, R. C., and H. I. Maibach. Bioavailability of organic solvents in soils: Input into biologically based dose-response models for human risk assessments. 1998 annual progress report. Office of Scientific and Technical Information (OSTI), June 1998. http://dx.doi.org/10.2172/13599.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Biological dose' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography